Cocoon Biotech has entered into service agreements with Camargo Pharmaceutical Services to provide end-to-end regulatory consulting and strategic development services for Cocoon’s pipeline of products initially developed for the treatment of osteoarthritis. The first joint program will involve biocompatible silk fibroin loaded with a small molecule therapeutic, and will include pre-investigational new drug (pre-IND) meeting planning and preparations through to new drug application (NDA) submissions.

“We are pleased to be partnering with Camargo, as they will be an important part of the team which will help execute our pre-IND and overall regulatory strategy in an effort to expedite our products into the clinic and ultimately into the hands of physicians who can help the many osteoarthritis patients in need of more effective medicines,” said Ailis Tweed-Kent, chief executive officer, Cocoon Biotech. “We believe that the vast experience that Camargo has in navigating regulatory agencies worldwide will be very beneficial to Cocoon both in the near-term and in years to come.”

Ken Phelps, president and chief executive officer, Camargo Pharmaceutical Services, said, “Our goal at Camargo is to guide our clients with the most cost- and time-effective strategy to navigate the 505(b)(2) regulatory pathway, while driving commercial success for our client-partners. Cocoon’s vision of enabling healthy, productive lives for patients worldwide by utilizing silk protein technology excites all of us at Camargo.”